Clinical trials
Phase 1 Anemia, Hemolytic, Autoimmune trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2015 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 10 |
| 2026 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Not yet recruiting | 10 |
| Recruiting | 7 |
| Completed | 5 |
| Terminated | 2 |
| Unknown status | 2 |
| Active, not recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 8 |
| Bioverativ, a Sanofi company | 3 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 3 |
| China Immunotech (Beijing) Biotechnology Co., Ltd. | 2 |
| Juventas Cell Therapy Ltd. | 2 |
| Zhejiang University | 2 |
| Beijing Boren Hospital | 1 |
| Changzhou No.2 People's Hospital | 1 |
| Circunited BioPharma (Shenzhen) Co., Ltd. | 1 |
| CytoCares Inc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Anemia, Hemolytic, Autoimmune | 28 |
| Lupus Erythematosus, Systemic | 5 |
| Myositis | 3 |
| Purpura, Thrombocytopenic, Idiopathic | 3 |
| Recurrence | 3 |
| Scleroderma, Systemic | 3 |
| Autoimmune Diseases | 2 |
| Amyloidosis | 1 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 |
| Arthritis, Rheumatoid | 1 |
Trials
Showing 26 to 28 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.